271 related articles for article (PubMed ID: 872134)
1. New steroidal alkylating agents in advanced stage D carcinoma of the prostate.
Mittelman A; Catane R; Murphy GP
Cancer Treat Rep; 1977; 61(2):307-10. PubMed ID: 872134
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine.
Catane R; Kaufman J; Mittelman A; Murphy GP
J Urol; 1977 Mar; 117(3):332-5. PubMed ID: 839597
[TBL] [Abstract][Full Text] [Related]
3. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
Murphy GP; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Soloway MS; Loening SA; Chu TM; Gaeta JF; Saroff J; Wajsman Z; Slack N; Scott WW
Trans Am Assoc Genitourin Surg; 1978; 70():69-71. PubMed ID: 753026
[TBL] [Abstract][Full Text] [Related]
4. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation.
Murphy GP; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Soloway MS; Loening SA; Chu TM; Gaeta JF; Saroff J; Wajsman Z; Slack N; Scott WW
J Urol; 1979 Jun; 121(6):763-5. PubMed ID: 458947
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with estramustine phosphate and predinimustine, two steroidal alkylating agents compounds [proceedings].
Catane R
Cancer Treat Rep; 1978 Aug; 62(8):1264-5. PubMed ID: 688269
[No Abstract] [Full Text] [Related]
6. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
[TBL] [Abstract][Full Text] [Related]
7. [Value of estramustine phosphate in the treatment of estrogen-resistant prostatic adenocarcinoma].
Toulouse J; Jung JL; Bittard M
J Urol (Paris); 1984; 90(1):27-33. PubMed ID: 6725973
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
9. National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: a progress report.
Johnson DE; Scott WW; Gibbons RP; Prout GR; Schmidt JD; Chu TM; Gaeta J; Saroff J; Murphy GP
Cancer Treat Rep; 1977; 61(2):317-23. PubMed ID: 141326
[TBL] [Abstract][Full Text] [Related]
10. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
11. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
12. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of estramustine phosphate (Estracyt) on prostatic cancer].
Murase T; Mitsuya H; Honda N; Fukatu H; Aota Y; Shinoda M; Yoshida K; Sobajima T; Ohishi M; Tsumura Y
Hinyokika Kiyo; 1989 Jan; 35(1):179-85. PubMed ID: 2729015
[TBL] [Abstract][Full Text] [Related]
14. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
15. Estramustine phosphate in the treatment of advanced malignant melanoma.
Lopez R; Karakousis CP; Didolkar MS; Holyoke ED
Cancer Treat Rep; 1978 Sep; 62(9):1329-32. PubMed ID: 688276
[TBL] [Abstract][Full Text] [Related]
16. Oral estramustine phosphate. Prolonged therapy for advanced carcinoma of prostate.
Catane R; Mittelman A; Kaufman J; Murphy GP
N Y State J Med; 1976 Nov; 76(12):1978-81. PubMed ID: 1069190
[No Abstract] [Full Text] [Related]
17. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of advanced carcinoma of the prostate with estramustine phosphate (estracyt)].
Lancina Martín JA; Chantada Abal V; Lamas Meilan AC; González Martín M
Actas Urol Esp; 1984; 8(5):399-402. PubMed ID: 6524487
[No Abstract] [Full Text] [Related]
19. Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt).
Vahlensieck W; Wegner G
Scand J Urol Nephrol Suppl; 1980; 55():147-9. PubMed ID: 6938018
[TBL] [Abstract][Full Text] [Related]
20. [Estracyt therapy in advanced prostate cancer: current status and personal results].
Nagel R; Leistenschneider W
Urologe A; 1983 May; 22(3):162-6. PubMed ID: 6683899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
